Back

ACEI plus GLP1-RA or SGLT2i, as well as ARNI, exerted distinct protective effects against diabetic nephropathy and heart failure with preserved ejection fraction in eNOS-/- dbdb mice.

11 May 2026 (08:30 - 09:15)
Organised by: Logo
Congress Presentation Part of: Frontiers in basic and translational heart failure research Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Kaikai Yu

Nantong (China)

6 More presentations in this session

Presentation thumbnail
The gut-heart axis: fecal microbiome shifts following SGLT2 inhibitor initiation in heart failure - a pilot study
Miss D. Teshuva (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
Effects of sodium-glucose cotransporter 2 inhibitors on cardiac metabolism, assessed by phosphorus magnetic resonance spectroscopy, in patients with heart failure
Associate Professor P. Rubis (Krakow, PL)
Abstract Slides Video
Presentation thumbnail
Epirubicin promotes coronary endothelial senescence and dysfunction with induction of pro-inflammatory and pro-thrombotic responses: role of the AT1R/NADPH oxidases/SGLT2 pro-oxidant pathway
Mr L. Axenbeck (Strasbourg, FR)
Abstract Slides Video
Presentation thumbnail
The effect of ARNI and SGLT2i therapies on the inflammasome pathway in myocardial heart transplantation biobank samples.
Doctor D. Nagy (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Efficacy of interleukin-1 blockade for prevention of heart failure outcomes in patients with prior myocardial Infarction: a systematic review and meta-analysis of 10301 patients
Miss B. Tran (Debrecen, HU)
Abstract Slides Video

Access the full session

Session thumbnail
Frontiers in basic and translational heart failure research

The Event

Event poster

Heart Failure 2026

11 May 2026 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Distinct cellular and molecular trajectories leading to subclinical diastolic dysfunction and the progression to HFpEF
thumbnail
Congress Presentation
A new era in modeling metabolic and hemodynamic stressors in HFpEF
thumbnail
Congress Presentation
Treatment of diastolic dysfunction by targeting beta-adrenergic receptors in vivo in a murine model of cardiometabolic HFpEF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources